Gilead Signs an Exclusive License Agreement with Rockefeller University for its Portfolio of HIV Abs

Gilead Sciences Receives the US FDA Advisory Committee’s Recommendation on Approval of Descovy for PrEP

Shots:

  • Rockfeller to receive up front, milestones plus royalties on sales and will retain rights to perform non-clinical and early-stage clinical research on the portfolio of HIV Abs. Gilead to get exclusive rights to develop and commercialize Rockefeller’s full portfolio of HIV bNAbs
  • The focus of the agreement is to enhance Gilead’s HIV pipeline and will advance academic programs into potential future products
  • 3BNC117 and 10-1074 are clinical-stage products with the ability to be used as HIV long-acting therapies for treatment and prevention

Click here to read full press release/ article | Ref: Gilead | Image: Twitter